PRME
Prime Medicine, Inc.
Key Financials
Revenue
$4.6M
↑ 55.3%
Operating Income
$-208350000
↓ 2.9%
Net Income
$-201142000
↓ 2.7%
EPS (Diluted)
$-1.35
↑ 18.2%
Cash & Equivalents
$63.0M
↓ 65.5%
Total Liabilities
$221.9M
↑ 53.7%
Total Assets
$342.7M
↑ 15.2%
Shareholders' Equity
$120.9M
↓ 21.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/17/2026 | View on SEC |
| 3 | 4/17/2026 | View on SEC |
| 8-K | 4/16/2026 | View on SEC |
| EFFECT | 3/4/2026 | View on SEC |
| S-8 | 3/3/2026 | View on SEC |
| POS AM | 3/3/2026 | View on SEC |
| 10-K | 3/3/2026 | View on SEC |
| POSASR | 3/3/2026 | View on SEC |
| 8-K | 3/3/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PRME |
| Company Name | Prime Medicine, Inc. |
| CIK | 1894562 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-465-0013 |